Journal ArticleDOI
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs.
Reads0
Chats0
TLDR
The epidermal growth factor receptor (EGFR) is a rational target for cancer therapy because it is commonly expressed at a high level in a variety of solid tumours and it has been implicated in the control of cell survival, proliferation, metastasis and angiogenesis.About:
This article is published in European Journal of Cancer.The article was published on 2003-07-01. It has received 249 citations till now. The article focuses on the topics: Epidermal growth factor & Receptor expression.read more
Citations
More filters
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Journal ArticleDOI
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Mauro Moroni,Silvio Veronese,Silvia Benvenuti,Giovanna Marrapese,Andrea Sartore-Bianchi,Federica Di Nicolantonio,Marcello Gambacorta,Salvatore Siena,Alberto Bardelli +8 more
TL;DR: It is proposed that the response to antiEGFR treatment has a genetic basis and suggest that patients might be selected for treatment on the basis of EGFR copy number.
Journal ArticleDOI
Mechanisms of drug resistance in cancer chemotherapy.
TL;DR: Attempts to overcome resistance mainly involve the use of combination drug therapy using different classes of drugs with minimally overlapping toxicities to allow maximal dosages and with narrowest cycle intervals, necessary for bone marrow recovery.
Journal ArticleDOI
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
John C. Sok,Francesca M. Coppelli,Sufi M. Thomas,Miriam N. Lango,Sichuan Xi,Jennifer L. Hunt,Maria L. Freilino,Michael W. Graner,Carol J. Wikstrand,Darell D. Bigner,William E. Gooding,Frank B. Furnari,Jennifer R. Grandis +12 more
TL;DR: EGFRvIII is expressed in HNSCC where it contributes to enhanced growth and resistance to targeting wild-type EGFR, and the antitumor efficacy of EGFR targeting strategies may be enhanced by the addition of EG FRvIII-specific blockade.
Journal ArticleDOI
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
TL;DR: The role of EGfr in cancer, different types of EGFR inhibitors, preclinical and clinical status of EG FR inhibitors as well as summarized the recent efforts made in the field of molecular EGFR targeting are outlined.
References
More filters
Journal ArticleDOI
Untangling the ErbB signalling network
Yosef Yarden,Mark X. Sliwkowski +1 more
TL;DR: When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion.
Journal ArticleDOI
Epidermal growth factor-related peptides and their receptors in human malignancies
Journal ArticleDOI
EGFR and cancer prognosis
TL;DR: The EGFR was found to act as a strong prognostic indicator in head and neck, ovarian, cervical, bladder and oesophageal cancers, and in non-small cell lung cancer (NSCLC), EGFR expression only rarely was related to patient outlook.
Journal ArticleDOI
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Jennifer R. Grandis,Mona F. Melhem,William E. Gooding,Roger Day,Valerie A. Holst,Marilyn M. Wagener,Stephanie D. Drenning,David J. Tweardy +7 more
TL;DR: Quantitation of EGFR and TGF-a protein levels in primary head and neck squamous cell carcinomas may be useful in identifying subgroups of patients at high risk of tumor recurrence and in guiding therapy.
Journal Article
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
TL;DR: A mini-review describes the EGFR inhibitors in clinical development and preliminary results from Phase I and II trials in patients with advanced disease demonstrate that ZD1839 and OSI-774 have an acceptable tolerability profile and promising clinical efficacy in Patients with a variety of tumor types.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more